Valeant Pharmaceuticals to Announce 2009 Third Quarter Results on November 2, 2009

Saturday, October 24, 2009 General News J E 4

ALISO VIEJO, Calif., Oct. 23 Valeant Pharmaceuticals International (NYSE: VRX) today announced that it will host a conference call and a live Internet webcast along with a slide presentation on Monday, November 2, 2009 at 10:00 a.m. EST (7:00 a.m. PST) to discuss results for the 2009 third quarter.


The dial-in number to participate on this call is (877) 295-5743, confirmation code 34747409. International callers should dial (973) 200-3961, confirmation code 34747409. A replay will be available approximately two hours following the conclusion of the conference call to Monday, November 16, 2009, and can be accessed by dialing (800) 642-1687 or (706) 645-9291, confirmation code 34747409.

The webcast and slide presentation will be hosted in the investor relations section of its corporate Web site at Participants should allow approximately five to 10 minutes prior to the call's start time to visit the site and to download any streaming media software needed to listen to the Internet webcast. An online archive of the webcast will be available following the end of the live call in the webcast archive portion of the investor relations section at

About Valeant

Valeant Pharmaceuticals International (NYSE:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at

Contact: Laurie W. Little 949-461-6002

SOURCE Valeant Pharmaceuticals International


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
October 2009 Mayo Clinic Women's HealthSource High...
WebMD Announces Completion of Merger with HLTH Cor...